Of the estimated 400 million patients with chronic hepatitis B (CHB) globally, approximately 75% are Asians, representing a clinically important subgroup with a higher risk of cirrhosis and hepatocellular carcinoma than Caucasian patients. This review summarizes recent data from clinical long-term and real-life studies of entecavir and tenofovir, the recommended first-line oral therapies for treating CHB, in nucleoside/nucleotide-naive Asian CHB patients with compensated or decompensated liver disease. Long-term treatment with entecavir or tenofovir achieved profound and durable virological suppression, and led to improved liver histology and function. The data presented in this review will help physicians in making evidence-based decision choices regarding first-line antiviral therapy and long-term management in Asian CHB patients.
References
1.
LiangX., BiS., YangW.Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis B vaccination. Vaccine2009; 27: 6550–6557.
KowdleyK.V., WangC.C., WelchS., RobertsH., BrosgartC.L.Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology2012; 56: 422–433.
4.
HuK.Q., PanC.Q., GoodwinD.Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci2011; 56: 3163–3171.
5.
ChungP.W., SuenS.H., ChanO.K., LaoT.H., LeungT.Y.Awareness and knowledge of hepatitis B infection and prevention and the use of hepatitis B vaccination in the Hong Kong adult Chinese population. Chin Med J (Engl)2012; 125: 422–427.
6.
LiawY.F., Raptopoulou-GigiM., CheinquerH.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology2011; 54: 91–100.
7.
LiawY.F., SungJ.J., ChowW.C.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med2004; 351: 1521–1531.
8.
ChangT.T., LiawY.F., WuS.S.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology2010; 52: 886–893.
9.
PapatheodoridisG.V., LamperticoP., ManolakopoulosS., LokA.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol2010; 53: 348–356.
10.
TongM.J., PanC.Q., HannH.W.The management of chronic hepatitis B in Asian Americans. Dig Dis Sci2011; 56: 3143–3162.
11.
European Association for the Study of the Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol2012; 57: 167–185.
12.
LiawY.F., KaoJ.H., PiratvisuthT.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int2012; 6: 531–561.
CaoG.W.Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol2009; 15: 5761–5769.
15.
FattovichG., BortolottiF., DonatoF.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol2008; 48: 335–352.
16.
YangH.I., YehS.H., ChenP.J.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst2008; 100: 1134–1143.
17.
NiY.H., ChangM.H., WangK.J.Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology2004; 127: 1733–1738.
18.
ChenC.H., LeeC.M., LuS.N.Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol2005; 43: 6000–6006.
19.
KaoJ.H., ChenP.J., LaiM.Y., ChenD.S.Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology2003; 124: 327–334.
20.
LiuC.J., ChenB.F., ChenP.J.Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis2006; 193: 1258–1265.
21.
MalikA., AsimM.Ligase chain reaction as a modality for the detection of point mutation in precore region of HBV related HCC cases. Hepatology International2011; 5: 308.
22.
PanC., ZengZ., HuK.Clinical features of chronic hepatitis B (CHB) in treatment naive Asian patients with positive HBeAg and co-existing precore and/or basal core promoter (PC/BCP) mutations. Gastroenterology2009; 136Suppl 1: A-865.
23.
PanC., ChanY.F., BansalR.Treatment response to peginterferon alpha-2A (PEG-IFN) in HBeAg positive chronic hepatitis B (CHB) patients with co-existing precore and/or basal core promoter mutations. Hepatology2009; 50: 514A.
24.
WuI.C., ShiffmanM.L., TongM.J.Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis2008; 47: 1305–1311.
25.
ChangT., ShiffmanM.L., TangM.Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB). Gastroenterology2006; 130: A-846.
26.
YaoG., XuD., WangB.A phase II study in China of the safety and antiviral activity of entecavir in adults with chronic hepatitis B infection. Hepatology2003; 38Suppl 4: 711A.
27.
FungJ., LaiC.L., TanakaY.The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol2009; 104: 1940–1946.
28.
SongB.C., SuhD.J., LeeH.C., ChungY.H., LeeY.S.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology2000; 32: 803–806.
29.
ChaungK.T., HaN.B., TrinhH.N.High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol2012; 46: 865–870.
30.
ZhangJ.M., XuY., WangX.Y.Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis2007; 44: 1161–1169.
31.
YaoG., ChenC., LuW.Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int2007; 1: 365–372.
32.
ShindoM., ChayamaK., MochidaS.Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, Phase II clinical trial. Hepatol Int2009; 3: 445–452.
33.
KobashiH., TakaguchiK., IkedaH.Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol2009; 24: 255–261.
34.
GishR.G., TsaiN., PanC.Efficacy and safety of entecavir in nucleos(t)ide naive asians with HBeAg-positive and -negative chronic hepatitis B: results from studies ETV-022/027. Hepatology2010; 52: 561A.
35.
LeeS.S., HeathcoteJ., SievertW.Tenofovir disoproxil fumarate (TDF) versus adefovir in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in studies 102 and 103. Hepatology2008; 48: 746A.
36.
PanC., ChanS., TrinkH.Tenofovir disproxil fumarate (TDF) shows similar virological suppression and safety between Asians and non-Asians with chronic hepatitis B (CHB). Hepatol Int2011; 5: 130.
37.
YaoG., XuD., RenH.Three years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naive patients with undetectable HBV DNA: results from studies ETV-023 and -050. Hepatol Int2008; 2: A162.
38.
YokosukaO., TakaguchiK., FujiokaS.Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol2010; 52: 791–799.
39.
PanC.Q., TongM., KowdleyK.V.High Rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol2012; 10: 1047–1050e1.
40.
ChangT.T., LaiC.L., KewY.S.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology2010; 51: 422–430.
41.
GaneE., LeeS.S., HeathcoteE.J.Four years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B, preliminary analysis. Hepatology2010; 52: 559A.
42.
GaneE.J., MarcellinP., SievertW.Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology2011; 54: 1038A.
43.
MarcellinP., ButiM., GaneE.J.Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology2012; 54: 1011A.
44.
HouJ., RenH., WangY.Efficacy and safety of entecavir treatment in a heterogenous CHB population in a real-life clinical practice setting in China. Hepatol Int2011; 5: 146.
45.
SetoW.K., LaiC.L., FungJ., YuenJ.C., WongD.K., YuenM.F.Outcome of 4-year treatment of entecavir for treatment-naive chronic hepatitis B. J Hepatol2011; 54Suppl 1: S301.
46.
YuenM.F., SetoW.K., FungJ., WongD.K., YuenJ.C., LaiC.L.Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol2011; 106: 1264–1271.
47.
HaN.B., HaN.B., GarciaR.T.Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci2011; 56: 2423–2431.
48.
ChanS., PanC., BaeH.Tenofovir disoproxil fumarate (TDF) demonstrates good efficacy and safety in Asians with chronic hepatitis B (CHB) in real-life settings. Hepatol Int2011; 5: 131.
49.
LinB., HaN.B., LiuA.Low incidence of hepatitis B e antigen (HBeAg) seroconversion with oral monotherapy in chronic hepatitis B (CHB) treatment-naive patients at year 1 in clinical practice. Hepatology2011; 54: 1045A.
50.
ChangT.T., LaiC.L., YoonS.K.Long-term virologicalal suppression, resistance and histological improvement in nucleos(t)ide-naive Asian chronic hepatitis B patients treated with entecavir in studies ETV-022/-027/-901. Hepatol Int2011; 5: 119.
51.
ColvinH.M., MitchellA.E.A national strategy for prevention and control of hepatitis B and C. Washington DC: National Academies Press2010.
52.
GuanR., LuiH.F.Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol2011; doi:10.4061/2011/918017.
53.
HenkelA.S., BuchmanA.L.Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol2006; 3: 202–209.
54.
ShermanM., ShafranS., BurakK.Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol2007; 21Suppl C: 5C–24C.
55.
ShimJ.H., LeeH.C., KimK.M.Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol2010; 52: 176–182.
56.
CheinquerH., Raptopoulou-GigiM., Kumar SarinS.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation: week 96 results. Hepatology International2011; 5: 272.
57.
LiawY.F., SheenI.S., LeeC.M.Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology2011; 53: 62–72.
GargH., SarinS.K., KumarM., GargV., SharmaB.C., KumarA.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology2011; 53: 774–780.
60.
BruixJ., ShermanM.Management of hepatocellular carcinoma: an update. Hepatology2011; 53: 1020–1022.
61.
HaN.B., HaN.B., AhmedA.Risk factors for hepatocellular carcinoma among patients with underlying chronic liver disease: a prospective study. Hepatology2010; 52: 682A.
62.
YuenM.F., WongD.K., FungJ.HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology2008; 135: 1192–1199.
63.
PapatheodoridisG.V., ManolakopoulosS., TouloumiG.Virologicalal suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut2011; 60: 1109–1116.
64.
JinY.J., ShimJ.H., LeeH.C.Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol2011; 26: 1380–1388.
65.
KobashiH., MiyakeY., IkedaF.Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res2011; 41: 405–416.
66.
TenneyD.J., RoseR.E., BaldickC.J.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology2009; 49: 1503–1514.
67.
YuenL., LittlejohnM., AyresA., EdwardsR., LocarniniS.A.Different patterns of primary antiviral drug resistance pathways in relation to hepatitis B virus genotypes: preferential selection of rtA181T+/- rtN236T in Asian versus European patients. Heptology2011; 5: 1066A.
68.
LangeC.M., BojungaJ., HofmannW.P.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology2009; 50: 2001–2006.
69.
LamperticoP., SoffrediniR., ViganoM.Effectiveness and safety of tenofovir disproxil fumarate in field practice: a multicentre European cohort study of 302 NUC-naive patients with chronic hepatitis B. J Hepatol2011; 54: S293.
70.
MaussS., BergerF., FilmannN.Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol2011; 55: 1235–1240.
71.
NguyenH-L, Al-FreahA., JoeD.A single centre, large ‘real-life’ cohort treated with tenfovir versus entecavir: no deterioration in tenofovir cohort over 12 months of thearpy. Hepatology2012; 54: 604A.
72.
Duarte-RojoA., HeathcoteE.J.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol2010; 3: 107–119.
73.
GaraN., GhanyM.G., ZhaoX., CollinsM.T., HoofnagleJ.H.Phosphate wasting nephropathy in patients with chronic hepatitis B treated with long-term adefovir or tenofovir. Hepatology2011; 54: 479A.
74.
TragulpiankitP., DhanaN., TanwandeeT., KittichaisriK., SitthimongkhonkarnP.The study of adverse drug reaction of tenofovir in chronic hepatitis B virus infection at Siriraj Hospital, Thailand. Hepatol Int2011; 5: 147.
75.
MannsM.P., AkarcaU.S., ChangT.T.Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf2012; 11: 361–368.
76.
TenneyD.J., PokornoskiK.A., RoseR.E.Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol2009; 50Suppl 1: S10.
77.
MarcellinP., HeathcoteE.J., CorsaA., LiuY., MillerM.D., KitrinosK.M.No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection. Hepatology2011; 54: 480A.
78.
GishR.G., ChangT.T., LaiC.L.Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat2010; 17: 16–22.
79.
LinC.L., KaoJ.H.The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol2011; 26Suppl 1: 123–130.
80.
LeeH., HuK., TonthatS.HBV treatment induced HBsAG seroconversion to anti-HBs in 9 Asian-American patients: experience in a community clinic. Hepatology2011; 54: 1034A.
81.
LimS.G.Should HBe seroconversion be an endpoint of treatment of chronic hepatitis B?Hepatol Int2011; 5: 41.
82.
TsengT.C., LiuC.J., WangC.C.Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther2009; 14: 203–210.
83.
YamauraT., TanakaE., MatsumotoA.A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter. J Med Virol2003; 70: 545–552.
84.
YuenM.F., WongD.K., ZhengB.J.Difference in T helper responses during hepatitis fares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J Viral Hepat2007; 14: 269–275.
85.
ZoutendijkR., SonneveldM.J., ReindersJ.G.Relationship between precore/ base core promoter mutants and serologicalal or virologicalal response in HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. Hepatology2011; 54: 1025A.
86.
WongG.L., WongV.W., ChanH.Y.Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther2012; 35: 1326–1335.
87.
ZoutendijkR., ReijndersJ.G., BrownA.Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virologicalal response. Hepatology2011; 54: 443–451.
88.
SonneveldM.J., ZoutendijkR., JanssenH.L.Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat2011; 18: 449–457.
89.
FungJ., LaiC.L., YoungJ.Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol2011; 106: 1766–1773.
90.
ZoutendijkR., HansenB.E., van VuurenA.J., BoucherC.A., JanssenH.L.Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis2011; 204: 415–418.
91.
HuttonD.W., BrandeauM.L., SoS.K.Doing good with good OR: supporting cost-effective hepatitis B interventions. Interfaces (Providence)2011; 41: 289–300.
92.
LokA.S., TrinkH.N., CarosiG., AkarcaU.S., GadanoA.Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the BE-LOW study. Hepatology2012; 54: 471A.
